A central question arising from the misdiagnosed clinical case [49] is why would a patient with a mutation in ABCA1 respond to a GSL substrate reduction therapy drug (miglustat) that is approved for treating NPC patients? This evidence concerns the gene ABCA1 and nasopharyngeal carcinoma.